Press Releases

Replay Available of Webcast Featuring Biothera Pharmaceutical Technology

EAGAN, MN — July 21, 2015 — Biothera Pharmaceutical Senior Vice President of Research Jeremy Graff, Ph.D. explained new research during a webinar today that shows how Imprime PGG targets multiple cells types that orchestrate a coordinated anti-tumor response involving both the innate and adaptive immune system. The webinar was part of the Biopharma Dealmarkers series hosted by Nature.com. Click here to for a replay of the webinar. Biothera...

Read More


Biothera Pharmaceutical Inc. Announces Board of Directors

EAGAN, Minn. — July 7, 2015 — Biothera Holding Corp. today announced the election of the board of directors for Biothera Pharmaceutical Inc., a wholly owned subsidiary that is developing a clinical stage cancer immunotherapy drug. The 10 directors are Brent Ahrens, Dr. Alex Giaquinto, Mike Grey, Dr. Annalisa Jenkins, Steven Karel, Andrew LaFrence, Richard Mueller, Walter Ogier, Dr. Bruno Osterwalder and Dr. Dwight Porter....

Read More


Biothera Announces Preclinical Research Collaboration with Eli Lilly and Company

EAGAN, MN — June 30, 2015 — Biothera announced today that it has signed a collaborative research agreement with Eli Lilly and Company (NYSE: LLY) to evaluate in preclinical models the combination of Biothera’s investigational immunotherapy Imprime PGG and Lilly’s anti-angiogenic therapy, ramucirumab (Cyramza®). Emerging data illustrate the enormous potential of therapies that activate the immune system to recognize and eradicate cancer cells. In many...

Read More


Biothera CMO to Address the World NSCLC Summit

BOSTON — June 23, 2015 — Biothera Chief Medical Officer Ada Braun, M.D., Ph.D. will deliver a presentation today on harnessing the innate immune system to increase the efficacy of cancer-targeted antibodies in non-small cell lung cancer (NSCLC) at the World NSCLC Summit. Biothera is pioneering the development of innate immune modulation to initiate a coordinated immune response to kill cancer cells. The company’s late...

Read More


Investigator-Sponsored Trial Evaluating Biothera’s Imprime PGG in Relapsed Indolent Non-Hodgkin Lymphoma

EAGAN, MN — June 22, 2015 — Biothera today announced that patient dosing has begun in an investigator-sponsored phase 2 trial of its investigational cancer immunotherapy, Imprime PGG, in combination with rituximab (Rituxan®) for relapsed indolent Non-Hodgkin Lymphoma (NHL). The trial is being conducted at the Dana-Farber Cancer Institute under the direction of Caron A. Jacobson, M.D., Instructor in Medicine, Harvard Medical School. “Rituximab, as...

Read More


Biothera to Participate in Webcast on Advances in Cancer Immunotherapy

EAGAN, MN — June 18, 2015 — Jeremy Graff, Ph.D., Senior Vice President, Pharmaceutical Research for Biothera, will participate in a BioPharma Dealmakers webcast featuring four companies developing cancer immunotherapies. The webcast is scheduled for 11:00 am ET on July 21. Webcast registration. The webcast will explore some of the challenges and opportunities of technologies at the cutting edge of cancer immunotherapy. Participants will learn...

Read More


Dan Conners Steps Down as Biothera Board Chairman and President of its Pharmaceutical Business

CEO Richard Mueller Elected Chairman Steve Smith Named Pharmaceutical President EAGAN, MN — June 5, 2015 — The Board of Directors of Biothera announced today that Dan Conners has stepped down as President of the company’s pharmaceutical business, as Chairman of the Board and as a Board member, effective immediately. The Board also announced that Richard Mueller, Biothera Chief Executive Officer since 2001, has been...

Read More


Imprime PGG-MAb Combination Therapy Achieves High Response Rate in Patients with Chronic Lymphocytic Leukemia

CHICAGO — May 31, 2015 — A combination of Biothera’s Imprime PGG and the monoclonal antibodies alemtuzumab and rituximab achieved responses in 13 of 14 (93%) patients with high-risk chronic lymphocytic leukemia, including nine (64%) complete responses. Results of this phase 1/2 study will be presented today at the American Society of Clinical Oncology (ASCO). Imprime PGG is an investigational cancer immunotherapy that directly modulates...

Read More


Integrated Safety Data from Two Phase 2 Cancer Studies Demonstrates Biothera’s Investigational Cancer Immunotherapy is Well Tolerated

CHICAGO — May 31, 2015 — A new, combined analysis of patient-level data from two randomized studies in non-small cell lung cancer provides further evidence that Biothera’s investigational immunotherapy Imprime PGG is safe and well tolerated, with adverse events generally consistent with complications of the disease and toxicities attributable to the cytotoxic drugs or monoclonal antibody therapies. Biothera presented the data yesterday at the American...

Read More


Biothera Presents Additional Data at ASCO on Durability and Characteristics of Response with Imprime PGG in Non-Small Cell Lung Cancer Study

CHICAGO — May 31, 2015 — Biothera’s investigational cancer immunotherapy Imprime PGG in combination with standard platinum-based doublet chemotherapy and the monoclonal antibody bevacizumab achieved rapid and lasting responses in patients with non-squamous non-small cell lung cancer (NSCLC). Tumor reduction was observed regardless of tumor burden (up to > 30 cm) or location of lesions at baseline (including lung, lymph nodes, adrenals, liver). These findings...

Read More



Page 4 of 6« First...23456